CAR-T cell therapy for active autoimmune disease flare-ups
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study tests an immune-cell treatment (CAR-T, called BRL-301) in people with certain autoimmune diseases that are active and hard to control. It may help your immune system calm down if standard treatments have not worked or your disease has returned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 65.
- Your blood test shows CD19 on B cells (a specific immune cell marker).
- Your blood counts and major organs are in a safe range (bone marrow, liver, kidneys, and blood clotting).
- You have an active form of one of these diseases: lupus, Sjögren’s with low platelets, systemic sclerosis with lung involvement, inflammatory muscle disease, ANCA vasculitis, or antiphospholipid syndrome—meeting the study’s severity rules.
- You have tried standard treatments that either did not work or your disease came back.
- You can sign consent, follow study visits, and meet birth-control rules if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells, to reset the immune system in people with severe autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome. It aims to reduce disease activity and potentially improve quality of life.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial is testing whether a type of immune cell therapy called CAR-T cells can help people with severe autoimmune diseases that have not improved with standard treatments. It may offer a new option for conditions like lupus, Sjogren's syndrome, or vasculitis when other therapies have failed.
Hear when a new Sjogren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.